Global Markets Directs, Lipodystrophy - Pipeline Review, H2 2014, provides an overview of the Lipodystrophys therapeutic pipeline.
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238883
This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238883
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Lipodystrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Lipodystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lipodystrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Lipodystrophy Overview
Therapeutics Development
Pipeline Products for Lipodystrophy - Overview
Pipeline Products for Lipodystrophy - Comparative Analysis
Lipodystrophy - Therapeutics under Development by Companies
Lipodystrophy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Lipodystrophy - Products under Development by Companies
Lipodystrophy - Companies Involved in Therapeutics Development
Aileron Therapeutics, Inc.
Ambrx, Inc.
AstraZeneca PLC
Bolder Biotechnology, Inc.
Theratechnologies Inc.
Zydus Cadila Healthcare Limited
Lipodystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALRN-5281 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-328 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tesamorelin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipodystrophy - Recent Pipeline Updates
Lipodystrophy - Dormant Projects
Lipodystrophy - Product Development Milestones
Featured News & Press Releases
May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin
Sep 18, 2013: EMD Serono Notifies FDA of a Shortage of Tesamorelin
Jul 08, 2013: Theratechnologies Inc./Request for Reconsideration in Canada: Meeting With Scientific Advisory Committee Authorized
Jun 28, 2013: Theratechnologies Provides Regulatory Update for Colombia
Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin
May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lipodystrophy, H2 2014
Number of Products under Development for Lipodystrophy - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Lipodystrophy - Pipeline by Aileron Therapeutics, Inc., H2 2014
Lipodystrophy - Pipeline by Ambrx, Inc., H2 2014
Lipodystrophy - Pipeline by AstraZeneca PLC, H2 2014
Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H2 2014
Lipodystrophy - Pipeline by Theratechnologies Inc., H2 2014
Lipodystrophy - Pipeline by Zydus Cadila Healthcare Limited, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Lipodystrophy Therapeutics - Recent Pipeline Updates, H2 2014
Lipodystrophy - Dormant Projects, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238883
This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238883
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Lipodystrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Lipodystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lipodystrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Lipodystrophy Overview
Therapeutics Development
Pipeline Products for Lipodystrophy - Overview
Pipeline Products for Lipodystrophy - Comparative Analysis
Lipodystrophy - Therapeutics under Development by Companies
Lipodystrophy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Lipodystrophy - Products under Development by Companies
Lipodystrophy - Companies Involved in Therapeutics Development
Aileron Therapeutics, Inc.
Ambrx, Inc.
AstraZeneca PLC
Bolder Biotechnology, Inc.
Theratechnologies Inc.
Zydus Cadila Healthcare Limited
Lipodystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALRN-5281 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-328 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tesamorelin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipodystrophy - Recent Pipeline Updates
Lipodystrophy - Dormant Projects
Lipodystrophy - Product Development Milestones
Featured News & Press Releases
May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin
Sep 18, 2013: EMD Serono Notifies FDA of a Shortage of Tesamorelin
Jul 08, 2013: Theratechnologies Inc./Request for Reconsideration in Canada: Meeting With Scientific Advisory Committee Authorized
Jun 28, 2013: Theratechnologies Provides Regulatory Update for Colombia
Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin
May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lipodystrophy, H2 2014
Number of Products under Development for Lipodystrophy - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Lipodystrophy - Pipeline by Aileron Therapeutics, Inc., H2 2014
Lipodystrophy - Pipeline by Ambrx, Inc., H2 2014
Lipodystrophy - Pipeline by AstraZeneca PLC, H2 2014
Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H2 2014
Lipodystrophy - Pipeline by Theratechnologies Inc., H2 2014
Lipodystrophy - Pipeline by Zydus Cadila Healthcare Limited, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Lipodystrophy Therapeutics - Recent Pipeline Updates, H2 2014
Lipodystrophy - Dormant Projects, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
No comments:
Post a Comment